Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (10,344,633)	$ (14,621,750)
Adjustments to reconcile net loss to net cash used in operating activities
Compensation cost for stock options granted	2,387,829	6,346,281
Disposal of assets	4,149	5,806
Depreciation and amortization	37,265	40,289
Change in fair value of stock-based compensation liability		1,741,919
Changes in operating assets and liabilities:
Prepaid expenses	(621,907)	79,791
Research and development tax rebate receivable	300,451	(50,882)
Other assets	(152,781)	28,878
Accounts payable	389,441	148,102
Accrued expenses	7,285	(165,343)
Payroll liabilities	(146,573)	48,398
Other current liabilities	1,779	(21,524)
Net cash used in operating activities	(8,137,695)	(6,420,035)
CASH FLOWS FROM INVESTING ACTIVITY
Purchase of furniture and equipment	(9,367)	(7,625)
Net cash used in investing activities	(9,367)	(7,625)
CASH FLOWS FROM FINANCING ACTIVITY
Proceeds from issuance of common stock, net of issuance costs	4,686,298
Payment of taxes related to net-exercise of employee stock options	(14,422)
Proceeds from exercise of warrants	0	11,336,710
Net cash provided by financing activities	4,671,876	11,336,710
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(3,475,186)	4,909,050
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE	12,691,136	10,490,493
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	9,215,950	15,399,543
SUPPLEMENTAL DISCLOSURES
Cash and cash equivalents	9,105,950	15,289,543
Restricted cash	110,000	110,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	9,215,950	15,399,543
NONCASH INVESTING AND FINANCING ACTIVITIES
Reclassification of stock-based liability awards to equity upon cancellation		3,151,944
Common stock issued upon cashless exercise of stock options	541,100
Conversion of Series B convertible preferred stock to common stock	$ 48,000	$ 1,707,999